Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study - Wikidata - wikimedia - TriplyDB

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study

http://www.wikidata.org/entity/Q33429467

about

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).

P2860

Q52670584-3CE79E0D-36A2-4D7E-BDD1-6BCB661FD001

P2860

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study

http://www.wikidata.org/entity/Q33429467

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Carboplatin-etoposide combinat ...... cancer: A retrospective study

@ast

Carboplatin-etoposide combinat ...... cancer: A retrospective study

@en

type

label

Carboplatin-etoposide combinat ...... cancer: A retrospective study

@ast

Carboplatin-etoposide combinat ...... cancer: A retrospective study

@en

prefLabel

Carboplatin-etoposide combinat ...... cancer: A retrospective study

@ast

Carboplatin-etoposide combinat ...... cancer: A retrospective study

@en

P1433

Q33429467-DB574FAF-B1FA-42DE-A775-E6C0038D9E62

P1476

Q33429467-E8E3A185-FC18-4A04-A90C-345E93C7F0F2

P2093

Q33429467-0CBC9AA9-4981-458C-88BA-E2012A3D13A1

Q33429467-3CD1F7A9-7FCF-4FEF-8C1D-B1FE95EB94F6

Q33429467-45634956-675C-44F9-83D3-E3CF9FF88495

Q33429467-7524980F-485C-474E-B4E2-32AD03C0503B

Q33429467-96779886-85DD-4843-913A-E08229C43474

Q33429467-A40A9215-8798-481D-8E62-CEA1AC010525

Q33429467-AA8C99E1-7D7A-4E7B-9B2F-94994AFC6147

Q33429467-BF9E418C-244F-4953-8570-166A2D6DB21C

Q33429467-D747D31B-5FE4-42A1-9CE4-A090819D26BC

Q33429467-F40D5E59-F8B5-4678-BF7F-D7019FB62B68

P2860

Q33429467-169F63A7-0635-46E7-8F6A-5B685D811CC6

Q33429467-1F0B0437-E512-4D39-BA6C-923CCA28A526

Q33429467-21F9E439-8C5F-472E-8790-9EB54DD622B0

Q33429467-29A75739-1EA0-4BDB-97AE-8AFCA00D54FC

Q33429467-31043EC5-4A1D-4FBA-82A4-4583E3DFBDE5

Q33429467-4C062DA5-91EB-499B-8289-0BE600E27765

Q33429467-555ED10A-6253-47E5-992B-25B2DEFEFEA0

Q33429467-72CC9AE2-5B12-4441-8DD9-EDA42ADC5CF2

Q33429467-7B27F771-017F-400B-9888-934F5132D6F4

Q33429467-95941880-9CC4-4359-9FE7-E5CE4F2FA163

P304

Q33429467-F37B8C4D-419A-46D1-B79C-033D9CAA9400

P31

Q33429467-6E0F436E-C001-4D88-9930-E41A0E7328CA

P356

Q33429467-028D5079-76CD-4923-9B9C-9D1E9CC54A29

P433

Q33429467-4679AD11-C009-4DC8-8EAD-397888F9BC2B

P478

Q33429467-FDBDF65E-ED45-41D0-8CE0-6FAB49E10AA5

P50

Q33429467-4AC982FE-E97C-4313-867F-46B979F1557B

P577

Q33429467-0B97A1BB-9487-47A4-9152-179AD18CFEA6

P5875

Q33429467-4B8CCD0F-F90B-4853-8456-CCDA1A3D7D72

P698

Q33429467-C1881501-233B-4F7D-AB0D-5530C56882E0

P932

Q33429467-C737614E-33CA-4E8C-AF97-4D43ABB7C71E

P356

P1433

Molecular and clinical oncology

P1476

Carboplatin-etoposide combinat ...... cancer: A retrospective study

@en

P2093

Astrid Pozet

http://www.w3.org/2001/XMLSchema#string

Erion Dobi

http://www.w3.org/2001/XMLSchema#string

Frederic Fiteni

http://www.w3.org/2001/XMLSchema#string

Guillaume Mouillet

http://www.w3.org/2001/XMLSchema#string

Hamadi Almotlak

http://www.w3.org/2001/XMLSchema#string

Matthieu Caubet

http://www.w3.org/2001/XMLSchema#string

Philippe Montcuquet

http://www.w3.org/2001/XMLSchema#string

Thierry N'guyen

http://www.w3.org/2001/XMLSchema#string

Tristan Maurina

http://www.w3.org/2001/XMLSchema#string

Ulrich Stein

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Increased survival with enzalutamide in prostate cancer after chemotherapy

Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

P304

1208-1212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2015.628

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Antoine Thiery-vuillemin

P577

2015-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282464679

http://www.w3.org/2001/XMLSchema#string

P698

26807222

http://www.w3.org/2001/XMLSchema#string

P932

4665308

http://www.w3.org/2001/XMLSchema#string